|Mr. Mark Crossley||CEO & Exec. Director||1.01M||N/A||N/A|
|Mr. Ryan Preblick||CFO & Exec. Director||N/A||N/A||N/A|
|Dr. Christian Heidbreder||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Jason Thompson||VP of Investor Relations||N/A||N/A||N/A|
|Mr. Javier Rodriguez||Chief Legal Officer||N/A||N/A||N/A|
|Ms. Cynthia Cetani||Chief Integrity & Compliance Officer||N/A||N/A||N/A|
|Mr. Jon Fogle||Chief HR Officer||N/A||N/A||N/A|
|Mr. Richard Simkin||Chief Commercial & Strategy Officer||N/A||N/A||N/A|
|Ms. Sue Learned||Sr. VP of Global Clinical Devel.||N/A||N/A||N/A|
|Hillel West||Chief Manufacturing & Supply Officer||N/A||N/A||N/A|
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's products focuses on treating substance use disorder, opioid use disorder, and schizophrenia. It offers SUBLOCADE injection for subcutaneous use; SUBOXONE sublingual film; and PERSERIS for extended-release injectable suspension, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company is also involved in finance activities. It operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Indivior PLC’s ISS Governance QualityScore as of November 1, 2019 is 10. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 1; Compensation: 8.